추천 제품
제품명
Cisplatin, Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation.
Quality Level
설명
Merck USA index - 14, 2317
분석
≥98% (HPLC)
양식
solid
제조업체/상표
Calbiochem®
저장 조건
OK to freeze
색상
yellow
solubility
PBS with 140 mM NaCl: 1 mg/mL
water with 154 mM NaCl: 1 mg/mL
DMSO: 10 mg/mL
배송 상태
ambient
저장 온도
2-8°C
InChI
1S/2Cl.2H3N.Pt/h;;2*1H3;
InChI key
JFUARQHXOQHNLK-UHFFFAOYSA-N
일반 설명
A platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation. Reported to sensitize glioma cells to TNF-α-induced apoptosis.
Note: Athough highly soluble in DMSO, Cisplatin is reported to be rendered inactive due to ligand displacement by the nucleophilic sulfur of DMSO. Sodium chloride solution in water (154 mM NaCl with or without 10 mg/ml mannitol) or PBS (with 140 mM NaCl) is recommended for solubilization prior to culture treatment.
Note: Athough highly soluble in DMSO, Cisplatin is reported to be rendered inactive due to ligand displacement by the nucleophilic sulfur of DMSO. Sodium chloride solution in water (154 mM NaCl with or without 10 mg/ml mannitol) or PBS (with 140 mM NaCl) is recommended for solubilization prior to culture treatment.
생화학적/생리학적 작용
Cell permeable: no
Primary Target
Induces apoptosis in cancer cells
Induces apoptosis in cancer cells
Product does not compete with ATP.
Reversible: no
경고
Toxicity: Toxic & Carcinogenic / Teratogenic (G)
재구성
Unstable in solution; reconstitute just prior to use.
기타 정보
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Hall, M.D., et al. 2014. Cancer Res. In press.
Duan, L., et al. 2001. J. Neurooncol.52, 23.
Mese, H., et al. 2000. Cancer Chemother. Pharmacol. 46, 241.
Von Hoff, D.D., and Rozencweig, M. 1979. in Adv. Pharmacol. Chemother.16, 279.
Duan, L., et al. 2001. J. Neurooncol.52, 23.
Mese, H., et al. 2000. Cancer Chemother. Pharmacol. 46, 241.
Von Hoff, D.D., and Rozencweig, M. 1979. in Adv. Pharmacol. Chemother.16, 279.
법적 정보
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
신호어
Danger
유해 및 위험 성명서
Hazard Classifications
Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
표적 기관
Respiratory system
Storage Class Code
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
이미 열람한 고객
Jinan Li et al.
Frontiers in molecular neuroscience, 15, 835448-835448 (2022-03-01)
Cisplatin is one of the most widely used chemotherapeutic drugs across the world. However, the serious ototoxic effects, leading to permanent hair cell death and hearing loss, significantly limit the utility of cisplatin. In zebrafish, the functional mechanotransduction channel is
Benjamin P Sharpe et al.
Cell reports. Medicine, 3(6), 100541-100541 (2022-06-23)
The chemotherapy resistance of esophageal adenocarcinomas (EACs) is underpinned by cancer cell extrinsic mechanisms of the tumor microenvironment (TME). We demonstrate that, by targeting the tumor-promoting functions of the predominant TME cell type, cancer-associated fibroblasts (CAFs) with phosphodiesterase type 5
Jiaqi Liu et al.
eLife, 10 (2021-12-18)
Gliomas are highly malignant brain tumors with poor prognosis and short survival. NAD+ has been shown to impact multiple processes that are dysregulated in cancer; however, anti-cancer therapies targeting NAD+ synthesis have had limited success due to insufficient mechanistic understanding.
Mohammed Hafiz Uddin et al.
Frontiers in oncology, 12, 908603-908603 (2022-07-19)
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) are currently being used for treating breast cancer patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic diseases. Despite durable responses, almost all patients receiving PARPis ultimately develop resistance and
Hyang Sook Seol et al.
Journal of gynecologic oncology (2023-01-21)
Advanced cervical cancer is still difficult to treat and in the case of recurrent cancer, it is desirable to utilize personalized treatment rather than uniform treatment because the type of recurrence is different for each individual. Therefore, this study aimed
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.